Our RPP PLUS panel includes all the pathogens covered by the RPP, such as COVID-19 (SARS-CoV-2), Influenza A & B, Respiratory Syncytial Virus (RSV), Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes (Group A), Adenovirus, Bocavirus, Bordetella pertussis, Chlamydophila pneumoniae, Coronaviruses (229E, HKU1, NL63, OC43), Enterovirus, Human Metapneumovirus (types A & B), Parainfluenza Virus (types 1-4), and Rhinovirus (types A & B). Additionally, it expands detection to include critical bacterial pathogens such as Acinetobacter baumannii, Bordetella bronchioseptica, Bordetella parapertussis, Enterobacter cloacae, Klebsiella aerogenes, Klebsiella pneumoniae, Legionella pneumophila, Parechovirus, Pneumocystis jirovecii, Pseudomonas aeruginosa, Staphylococcus aureus, and Methicillin/Oxacillin (mecA) resistant strains.

This extensive coverage provides unparalleled diagnostic capability, enabling healthcare providers to identify and treat a wide range of respiratory infections accurately. The RPP PLUS panel is essential for comprehensive respiratory diagnostics, particularly in settings where precision and speed are crucial for patient outcomes. With the ability to detect multiple pathogens, including antibiotic-resistant bacteria, this test supports informed clinical decisions and targeted therapeutic interventions.